DigestRedComo funciona
Red
/
Empresas
Qu
No verificado

Quince Therapeutics, Inc.

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaMedicina - VariosSalud

38 Comunicados de prensa

Ver todos los comunicados de prensa
09/02/2026
Mercado laboral
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives
Fuente
Quince Therapeutics, Inc.
Editor
Business Wire
1.00
0
29/01/2026
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Industria
Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia
Fuente
Quince Therapeutics, Inc.
Editor
Business Wire
1.00
0
28/01/2026
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Eventos
Industria
Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting
Fuente
Quince Therapeutics, Inc.
Editor
Business Wire
1.00
0
15/12/2025
Industria
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia
Fuente
Quince Therapeutics, Inc.
Editor
Business Wire
1.00
0
10/12/2025
Industria
Biotecnología
VIH, SIDA y enfermedades autoinmunes
Salud
Farmacéutica
Medicina - Varios
Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders
Fuente
Quince Therapeutics, Inc.
Editor
Business Wire
1.00
0
24/11/2025
Eventos
Ciencia
Biotecnología
Farmacéutica
Sanidad
Salud
VIH, SIDA y enfermedades autoinmunes
Medicina - Varios
Quince Therapeutics to Participate at Investor Events in December 2025
Fuente
Quince Therapeutics, Inc.
Editor
Business Wire
1.00
0
12/11/2025
Mercado de valores
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
Fuente
Quince Therapeutics, Inc.
Editor
Business Wire
1.00
0
10/11/2025
Industria
Ciencia
VIH, SIDA y enfermedades autoinmunes
Medicina - Varios
Biotecnología
Salud
Farmacéutica
Sanidad
Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
Fuente
Quince Therapeutics, Inc.
Editor
Business Wire
1.00
0
09/10/2025
Oncología
Salud
Ciencia
Farmacéutica
Biotecnología
Industria
Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting
Fuente
Quince Therapeutics, Inc.
Editor
Business Wire
1.00
0
25/09/2025
Industria
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study
Fuente
Quince Therapeutics, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0